Anyone buying marijuana stocks?

[KING WILL]

*************************************************************
Sunday Night News: AMRN CEO dangling carrot, Stockvadar-writes

Irrespective who you are, no one but an idiot wants to be short come 10 November. And why? The deck is clearly stacked in bullish favor. We think the pps will be over $30 if not $40 by then. Realize please--

Amarin's CEO has dangled the secondary and tertiary data like a proverbial carrot. They are saying, "We want to reveal this data before the world's cardiologists" and it's as bullish as it comes. And Vascepa is in cancer studies? Are you joking? Trig- and bad LDL is plenty enough!!!!

We read a lot about pps targets here, and we loan our own education. Stocks these days trade on sentiment, not intrinsic valuation. Regarding Amarin, that 10 Nov meeting will lift the lid off the pps price. Buy out talk? Ha! The market will ride this stock well above $100 on the way to $200. Why? Simply because the buying frenzy will be unstoppable. Only a pharma capable of a really big spend will have a chance to buy Amarin.

We're telling friends and family, get in on this ride higher! Buy-out talk is secondary to what Vascepa represents as a block-buster over the next decade.

This churning has been interesting (closing gaps), but we think it will rise above $20 this week and stay there. BUT THAT IS ONLY THE BEGINNING.

-sv (STRONG BUY at these levels)

**************************************************************

FMV Calculation: $60B buy-out on the table, Stockvadar-writes

Looking at 10 yr run with patent protection, and seeing how secondary/tertiary data will support liver, colon, and heart health above and beyond triglycerides and LDL (bad) cholesterol, and taking into account the mega-market size, we estimate a 10x multiple beyond the current $6B valuation, i.e. $60B, or $200/share. Depending on how the buy-out proceeds, Armarin's CEO may be aiming slightly higher, circla $75B to close the deal.

We do not hesitate to buy and hold shares at these bargain levels. Clearly, MMs are loading for what is coming in short order.

-sv (STRONG BUY



**************************************************


It’s a bit like the company just figured out how to genetically engineer trees that grow money. Imagine negotiating for the acquisition of a company that figured out how to engineer trees that grow money.



Is Amarin Corporation plc (NASDAQ:AMRN) Heading for a Bidding War? - FDA Headlines

 

[Rickdogg44]

FMV Calculation: $60B buy-out on the table, Stockvadar-writes

Looking at 10 yr run with patent protection, and seeing how secondary/tertiary data will support liver, colon, and heart health above and beyond triglycerides and LDL (bad) cholesterol, and taking into account the mega-market size, we estimate a 10x multiple beyond the current $6B valuation, i.e. $60B, or $200/share. Depending on how the buy-out proceeds, Armarin's CEO may be aiming slightly higher, circla $75B to close the deal.

We do not hesitate to buy and hold shares at these bargain levels. Clearly, MMs are loading for what is coming in short order.

-sv (STRONG BUY



**************************************************


It’s a bit like the company just figured out how to genetically engineer trees that grow money. Imagine negotiating for the acquisition of a company that figured out how to engineer trees that grow money.



Is Amarin Corporation plc (NASDAQ:AMRN) Heading for a Bidding War? - FDA Headlines

200 per share? No way. Isn this on everyone radar by jump to 20s from 2s last month?

 

[KING WILL]

No, its on the Radar because they released the results of their study.

That Monday the stock went from 3 to 12.

 

[Rickdogg44]

Another one Im looking at a company out of Sweden, stock sym is EARS.

They made some kind of gel and helps restore hearing loss.

I haven't pulled the trigger yet but today it went up 39% to .93 cents PS.

How you feeling about EARS now?

 

[KING WILL]

How you feeling about EARS now?

Got in on Monday, sold on Monday.

Got more shares of AMRN.

Might get back in later, cuz that product they are working on works (on stage 2 of testing).

 

[KING WILL]

Not sure if yall seen it:


It’s a bit like the company just figured out how to genetically engineer trees that grow money. Imagine negotiating for the acquisition of a company that figured out how to engineer trees that grow money.

It’s not going to be easy to have the upper hand. But, if you’re Mega Pharmaceuticals Inc., you certainly don’t want to let Giganticus BioPharm Inc. beat you to the deal because whoever owns those 25 patents is going to control a great deal of the landscape for one of the most significant treatment areas in the entire addressable healthcare market.

That would seem to lay the groundwork for some type of bidding war at some stage down the road

Is Amarin Corporation plc (NASDAQ:AMRN) Heading for a Bidding War? - FDA Headlines

 

[GreenGrass]

any cheap shares? some companies just starting up or waiting and to see the results after a certain time frame

 

[KING WILL]

any cheap shares? some companies just starting up or waiting and to see the results after a certain time frame

I have a list for you. I was looking a some penny stocks to invest in a came cross this video about 3-4 weeks ago.

As far as I can remember these are all Biopharmaceutical Companies.

I have the Company Symbol, Sig Event Date, the Stock prick as of about 2 weeks ago.

Sig Event Date was normally when their product went/or is going up for some kind of review.

PLX 10/5 .56
TRVN 10/11 N/A (Product was rejected)
ACRX N/A 4.15 (Product was approved) Im invested in this one.
AVEO N/A 2.16
BLRX N/A 1.29
NTGN N/A 9.92
AGLE 10/19 9.07
IMDZ N/A 2.79
EARS ------------------) (Product was approved) I took my profits on Mon. Might be worth looking into tho.
EYPT 11/5 3.06
CRVS 11/9 8.62
CPRX 11/28 3.09
THERF 11/3 6.65

GL

 

[KING WILL]

Amarin Corporation plc (NASDAQ:AMRN), as we have noted several times, is in a very special situation at present. We’ve likened it to a company that discovered how to make trees that grow money.


Will Amarin Corporation plc (NASDAQ:AMRN) Wait for the Express? - FDA Headlines

 

[KING WILL]

************Weekend Update: 76 yr old BOD cashes in on $30M loan in senior notes, Stockvadar-writes

For those who may have missed our analysis, consult our post entitled "News: Amarin cleans balance sheet in preparation for buy-out offers, Stockvadar-writes"; in the many threads (including links to confirm) you'll discover the following--

A few years back, a board member Patrick "Paddy" O'Sullivan through his own firm, Corsicanto, a subsidiary under Amarin (note the internal control) purchased $30M senior notes indebting Amarin wherein now Paddy at age 76 or so is cashing in for Amarin shares. Paddy's invested in other firms before, sits on the BOD at Allergan, and has many contacts in the pharmaceutical industry including a recognizable award from Denmark as he once led Leo Pharma.

Clearly, Amarin and Paddy are working together, strengthening Amarin's balance sheet, and preparing for what has already been a wave of inquirers surrounding Vascepa. We estimate a $60B buy-out (as a base figure) or ~$200/share. Some who see the stock at $19-20/share and at ~$6B, wonder how we could derive a buy-out price 10x higher; the answer is, because everyone is waiting for the Nov 10 revelation of data to determine the scope (key word), or in financial terms, the multiples of forward revenue since Amarin has this wrapped up for ~10 years going forward. Point is, if Amarin's presentation (and we believe it will) presents data showing the benefit of adding Vascepa to statin(s) to further lower triglycerides and cholesterol, and additionally shows other long term benefits (e.g. liver, colon, intestines, heart), as well as longevity, then the market potential will exceed our $60B base. BTW, sNDA will be filed in early Q1 2019 following the presentation and at least one scholarly publication that no doubt will be slated for publication ASAP. Why $60B minimum? Think about it. If doctors add Vascepa to only 25% of all statin prescription, do you not realize how mega-huge that is? BTW, we think Astra-Zeneca will be among those bidding, but others like Novartis, Pfizer, cannot be ruled out.

Anyway, Paddy O'Sullivan helped Amarin at a time when they needed it. Now in the latter years of his own life, Paddy is gaining additional shares and most likely he will very well hold them through Nov 10 and until the buy-out bid is confirmed.

Happy weekend. This is going higher in the weeks to come!

-sv (STRONG BUY)

 

[Rickdogg44]

@KING WILL

Props.

 

[KING WILL]

Np, just trying to post all of the info that I can.

Some did post a good question that I never seen a reply do.

In a $60B buyout, WTF does $30M matter, when it could be taken care of w/ the proceeds from the BO...

Another person posted that they are valuing a BO of between $68-$143 PPS. He wasn't as detailed as the SV Group is tho.

 

[Mr Rager]

So you recommend going heavy on AMRN? Expecting any dips soon?

 

[KING WILL]

So you recommend going heavy on AMRN? Expecting any dips soon?

Prolly will be a dip here and there.

Some Companies are buying up this stock right now.

Nov. 10th is will they will reveal all of the info of this study and its expected to go vey well and that should give the stock a good boost.

After that, its expected that BO offers will start rolling in.

Im def going to try to add some shares before the 10th.

 

[Mr Rager]

Prolly will be a dip here and there.

Some Companies are buying up this stock right now.

Nov. 10th is will they will reveal all of the info of this study and its expected to go vey well and that should give the stock a good boost.

After that, its expected that BO offers will start rolling in.

Im def going to try to add some shares before the 10th.

See any estimates on where this will top out by EOY? 1 Year outlook?
If the numbers look right, I might throw in big